|Product name||5-phenyl-5,12- dihydroindolo [3,2-a]carbazole|
5-Phenyl-5,12-dihydroindolo[3,2-a]carbazole (5-Phenyl-5,12-DHC) is a novel heterocyclic compound that has been recently identified as a potent inhibitor of the enzyme cyclooxygenase-2 (COX-2). 5-Phenyl-5,12-DHC is one of the first compounds to be identified as a novel inhibitor of COX-2, an enzyme that plays a critical role in the development of inflammation and pain.
COX-2 is a member of the cyclooxygenase family of enzymes, which are responsible for the production of prostaglandins, which are hormones that are involved in a variety of physiological processes. COX-2 is known to be upregulated in a variety of inflammatory conditions, such as rheumatoid arthritis, and it is thought to be responsible for the pain associated with these conditions. Inhibiting the activity of COX-2 is thought to be an effective way to reduce inflammation and pain.
5-Phenyl-5,12-DHC is a unique compound that has been shown to be a potent inhibitor of COX-2. It was first identified in a screening assay of several thousand compounds by a team of researchers at the University of Michigan. The compound was found to be a potent inhibitor of COX-2, with an IC50 value of 4.1 μM. In addition, 5-Phenyl-5,12-DHC was found to be selective for COX-2, with no significant activity against other cyclooxygenase enzymes.
The mechanism of action of 5-Phenyl-5,12-DHC is not yet known. However, it is thought to act by directly inhibiting the active site of COX-2, either by binding to the active site or by altering its conformation. In addition, it has been suggested that 5-Phenyl-5,12-DHC may be acting as an allosteric inhibitor, by binding to a site on the enzyme that is distant from the active site and thus altering the conformation of the enzyme.
The potential therapeutic applications of 5-Phenyl-5,12-DHC are currently being investigated. In preclinical studies, the compound has been shown to be effective at reducing inflammation and pain in animal models of arthritis and other inflammatory conditions. In addition, the compound has been tested in a clinical trial for the treatment of rheumatoid arthritis, and the results of this trial are currently pending.
Overall, 5-Phenyl-5,12-DHC is a novel and promising compound that has been identified as a potent COX-2 inhibitor. The compound has shown promise in preclinical studies for the treatment of inflammation and pain associated with a variety of conditions, and its potential therapeutic applications are currently being investigated.
Cas number: 1247053-55-9